Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Hepatitis b immunisation regimen and compositions

A kind of technology of hepatitis B, chronic hepatitis B, applied in a method and composition used in such scheme and method, the field of immunization scheme for the treatment of chronic hepatitis B

Pending Publication Date: 2020-10-16
GLAXOSMITHKLINE BIOLOGICALS SA
View PDF30 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] There remains an unmet need for treatments that can clear HBsAg to allow patients to safely discontinue NA therapy without virologic or clinical relapse

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hepatitis b immunisation regimen and compositions
  • Hepatitis b immunisation regimen and compositions
  • Hepatitis b immunisation regimen and compositions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0280] Example 1 - Evaluation of ChAd155-HBV (with and without hIi) priming in the HLA.A2 / DR1 transgenic mouse model and MVA-HBV enhanced

[0281] Target

[0282] The primary objective of this experiment was to determine whether priming with a dose of ChAd155-HBV (with or without hIi), followed by a booster dose of MVA-HBV, could induce the expression of a new gene in HLA.A2 / DR1 mice transgenic for human MHC-I / II molecules. Induces strong CD8 against HBc + T cell response. In addition, a head-to-head comparison between ChAd155-HBV with and without hli was performed to investigate that the hli sequence further increases HBc-specific CD8 + Potential for T-cell responses, as previously reported for other antigens [Spencer, 2014; Capone, 2014]. HBs-specific CD8 was also assessed + T-cell responses and HBc- and HBs-specific CD4 + T-cell and antibody responses.

[0283] Research design

[0284] HLA.A2 / DR1 mice (11 mice per group) were treated with 10 intramuscularly o...

Embodiment 2

[0302] Example 2 - HBc-HBs / AS01 in inbred mice (CB6F1) B-4 Immunogenicity studies

[0303] Target

[0304] The main objective of this immunogenicity study was to determine when in AS01 B-4 Whether HBc and HBs proteins can induce HBc- and HBs-specific humoral and T-cell responses when co-formulated in .

[0305] Research design

[0306] 6- to 8-week-old CB6F1 mice (30 mice per group) were treated with 50 µl AS01 on days 0, 14 and 28 B-4 The HBc, HBs or HBc-HBs (listed in the following table 2) prepared in the Chinese medicine were immunized intramuscularly three times. HBc- and HBs-specific T cell responses were measured on fresh PBL 7 days after the second and third dose, and anti-HBs and anti-HBc antibodies were measured 14 days after the second and third dose answer.

[0307] Table 2: Treatment Groups

[0308] Group antigen 1 1 µg HBc / AS01 B-4 (HBc / AS01 B-4 )

2 1 µg HBs / AS01 B-4 (HBs / AS01 B-4 )

3 1µg HBc + 1µg HBs / AS01 B-4...

Embodiment 3

[0319] Example 3 - Comparative Adjuvant Experiments in Inbred Mice (CB6F1)

[0320] Target

[0321] The main purpose of this experiment was to compare the 4:1 ratio with different adjuvants (alum, AS01 B-4 or AS01 E-4 ) HBc and HBs antigens formulated together or without adjuvant induced strong CD4 against both antigens + Capacity for T-cell and humoral responses.

[0322] Research design

[0323] CB6F1 mice aged 6 to 8 weeks (35 mice for groups 1-4 and 25 mice for group 5) were treated with alum, AS01 B-4 or AS01 E-4 The prepared HBc-HBs antigen (4µg-1µg) (listed in Table 3 below) was immunized intramuscularly three times. with AS01 B-4 Compared to AS01 E-4 The adjuvant system contains half the amount of immune enhancers QS-21 and MPL. HBc- and HBs-specific T cell responses were measured on fresh PBL 7 days after the second and third doses, after ex vivo restimulation with the pool of peptides for 6 hours, and after the second and third doses Anti-HBs and anti-HB...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human acomposition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

Description

[0001] field of invention [0002] The present invention relates to immunization regimens particularly suited for the treatment of chronic hepatitis B, methods for treating chronic hepatitis B and compositions for use in such regimens and methods. The protocols and methods involve administering a composition comprising a vehicle for delivery of a hepatitis B antigen and a composition comprising a recombinant hepatitis B antigen protein. [0003] Background of the invention [0004] Hepatitis B virus (HBV) infection is a major public health problem. Approximately 257 million people worldwide are infected with HBV [WHO, 2017]. The clinical course and outcome of HBV infection are largely dependent on the age at infection and the complex interplay between viral and host immune responses [Ott, 2012; Maini, 2016]. Thus, exposure to HBV may lead to acute hepatitis, which resolves itself or may progress to various forms of chronic infection, including inactive hepatitis B surface ant...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P31/20A61K39/29A61K39/12C07K14/02A61K39/00
CPCA61K39/292A61K2039/545A61P31/20A61K39/12C07K14/02C12N2710/10341C12N2710/10343C12N2710/24141C12N2710/24143C12N2730/10134C12N2730/00071A61K39/00A61K39/29C12N15/86
Inventor V.阿门多拉B.巴亚特C.洛林V.B.瓦西莱夫A.维特利
Owner GLAXOSMITHKLINE BIOLOGICALS SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com